VETONE- osmosol-r sodium chloride,sodium gluconate,sodium acetate,potassium chloride and magnesium chloride injection, solution 
MWI

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

VETone®            OsmoSol™–R
                         Multiple Electrolyte Injection Type 1‚ USP

STERILE NONPYROGENIC SOLUTION
For Animal Use Only

DESCRIPTION

VetOne OsmoSol–R (Multiple Electrolyte Injection, Type 1, USP) is a sterile, non–pyrogenic

isotonic solution intended for fluid and electrolyte replenishment in single dose containers.

May be administered intravenously or subcutaneously using aseptic technique. It contains

no antimicrobial agents· Discard any unused portion. The pH is adjusted with Hydrochloric

Acid and⁄or Sodium Hydroxide. Composition,osmolarity, pH and ionic concentration are

shown in Tabe 1·

image description

Osmolarity (mOsmol⁄L) (calc):294 mOsmol per litre

pH: 6.6 (limit 4.0 to 8.0)

The container is free of PVC and phthalates. The container meets the requirements of USP and is

registered with US FDA

CLINICAL PHARMACOLOGY

A multiple electrolyte intravenous solution is intended to restore the electrolyte balance and

water for hydration· It is capable of inducing diuresis depending on the clinical condition of

the patient and produces a metabolic alkalinizing effect. Acetate and gluconate ions are

metabolized ultimately to carbon dioxide and water‚ which requires the consumption of

hydrogen cations·

INDICATIONS AND USAGE

VetOne OsmoSol–R (Multiple Electrolyte Injection‚ Type 1‚ USP) is indicated as a source

of water and electrolytes for all species· It is also used as an alkalinizing agent.

CONTRAINDICATIONS

None known

WARNINGS

The introduction of additives to any solution, regardless of type of container, requires

special attention to ensure that no incompatibilities result. While some incompatibilities

are readily absorbed, one must be aware that subtle physical, chemical and pharmacological

incompatibilities can occur. The medical literature, the package insert and other available

sources of information should be reviewed for thorough understanding of possible

incompatibilities·

VetOne OsmoSol–R (Multiple Electrolyte Injection, Type 1, USP) should be used with great

care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in

clinical states in which there exists edema and sodium retention.

VetOne OsmoSol–R (Multiple Electrolyte Injection, Type 1, USP) should be used with great

care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in

which potassium retention is present.

VetOne OsmoSol–R (Multiple Electrolyte Injection, Type 1, USP) should be used with great

care in patients with metabolic or respiratory alkalosis. The administration of acetate or

gluconate ions should be done with great care in those conditions in which there is an

increased level or an impaired utilization of these ions, such as severe hepatic insufficiency·

The intravenous administration of VetOne OsmoSol–R (Multiple Electrolyte Injection,

Type 1, USP) can cause fluid and⁄or solute overloading resulting in dilution of serum

electrolyte concentrations, over-hydration, congested states, or pulmonary edema.

The risk of dilutional states is inversely proportional to the electrolyte concentrations

of the injection. The risk of solute overloading causing congested states with peripheral

and pulmonary edema is directly proportional to the electrolyte concentrations of the

injections.

In patients with diminished renal functon, administration of VetOne OsmoSol–R (Multiple

Electrolyte Injection, Type 1, USP) may result in sodium or potassium retention·

ADVERSE REACTIONS

Adverse reactions may occur due to the solution or the technique of administration

including febrile response, infection at the site of injection or alergic reactions.

Prolonged intravenous infusion of this type of product may cause venous thrombosis

or phlebitis extending from the site of injection, extravasation, and hypervolemia·

If an adverse reaction does occur, discontinue the infusion and evaluate the patient,

institute appropriate therapeutic countermeasures, and save the remainder of the

fluid for examination if deemed necessary·

PRECAUTIONS

This is a single dose unit. It contains no preservatives. Use entire contents when first

opened·

Clinical evaluation and periodic laboratory determinations are necessary to monitor

changes in fluid balance, electrolyte concentrations, and acid base balance during 

prolonged therapy or whenever the condition of the patient warrants such evaluation.

VetOne OsmoSol–R (Multiple Electrolyte Injection, Type 1, USP) should be used with

caution. Excess administration may result in metabolic alkalosis·

Caution must be exercised in the administration of VetOne OsmoSol–R (Multiple

Electrolyte Injection, Type 1, USP) to patients receiving corticosteroids or corticotropin·

Do not administer unless soution is clear and both seal and container are intact·

Solution must be warmed to body temperature prior to administration and

administered at a slow rate. Use solution promptly following initial entry·

Reactions which may occur because of the solution or the technique of administration‚

include febrile response, infection at the Site of injection, extravasation, and

hypervolemia·

If an adverse reaction does occur, discontinue the infusion and evaluate the patient,

institute appropriate therapeutic countermeasures, and save the remainder of the

fluid for examination if deemed necessary·

DOSAGE AND ADMINISTRATION

To be used as directed by a licensed veterinarian. The dosage of the VetOne OsmoSol–R

(Multiple Electrolyte Injection, Type 1, USP) is dependent upon the age, weight and

clinical conditions of the patient as well as laboratory determinations. Parenteral

drug products should be inspected visually for particulate matter and dscoloration

prior to administration.

For use in one patient on one occasion only. Discard any unused portion. Care should

be taken with administration technique to avoid administration site reactions and

infection·

Additives may be incompatible. Complete information is not available. Those additives

known to be incompatible should not be used. Consult with Pharmacist, if available. If,

in the informed judgement of the veterinarian, it is deemed advisable to introduce

additives, use aseptic technique. Mix thoroughly when additives have been introduced.

Do not store solutions containing additives·

OVERDOSAGE

In an event of over-hydration or solute overload, re-evaluate the patient and institute

appropriate corrective measures. See Warnings, Precautions and Adverse Events·

PACKS SUPPLIED

VetOne OsmoSol–R (Multiple Electrolyte Injection, Type 1, USP) in plastic container is available

as follows:

image description
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat.

It isrecommended the product be stored at room temperature (86°F/30°C). Protect

from freezing·

DIRECTIONS FOR USE OF PLASTIC CONTAINER

To Open

Tear overwrap at slit and remove solution container. Some opacity of the plastic due to

moisture absorption during the sterilization process may be observed. This is normal

and does not affect the solution quality or safety. The opacity will diminish gradually.

Check for minute leaks by squeezing solution container firmly. If leaks are found,

discard solution as sterility may be impaired·

If supplemental medication is desired, follow directions below:

Preparation for Administration

1. Suspend container from eyelet support·

2. Remove plastic protector from inlet/outlet port at bottom of container.

3. Attach administration set.

To Add Medication

WARNING:Additives may be incompatible.

To add medication before solution administration

1. Prepare medication site.

2. Using syringe with 0.63mm to 0·80mm needle, puncture medication port and inject.

3. Mix solution and medication thoroughly. For high density medication such as potassium

    chloride, squeeze ports while ports are upright and mix thoroughly.

To add medication during solution administration

1. Close the clamp on the administration set.

2. Prepare medication site.

3. Using syringe with 0.63mm to 0·80mm needle, puncture medication port and inject.

4. Remove container from IV pole and/or turn to an upright position.

5. Evacuate both ports by squeezing them while container is in the upright position.

6. Mix solution and medication thoroughly·

7. Return container to in use position and continue administration·

CAUTION

FEDERAL LAW RESTRICTS THIS DRUG TO USE BY OR ON THE ORDER OF A LICENSED

VETERINARIAN

Made in Australia

Manufactured by:
Sypharma Pty Ltd
27 Healey Road Dandenong
Victoria 3175 Australia

Distributed by: MWI
Boise, ID 83705
www.VetOne.net


Iss. 04/18

OsmoSol™–R 1000ml

image description

VETONE 
osmosol-r sodium chloride,sodium gluconate,sodium acetate,potassium chloride and magnesium chloride injection, solution
Product Information
Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:13985-943
Route of AdministrationINTRAVENOUS, SUBCUTANEOUS
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
SODIUM CHLORIDE (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37, CHLORIDE ION - UNII:Q32ZN48698) SODIUM CHLORIDE526 mg  in 100 mL
Sodium Gluconate (UNII: R6Q3791S76) (SODIUM CATION - UNII:LYR4M0NH37, GLUCONIC ACID - UNII:R4R8J0Q44B) Sodium Gluconate502 mg  in 100 mL
Sodium Acetate (UNII: 4550K0SC9B) (SODIUM CATION - UNII:LYR4M0NH37, ACETATE ION - UNII:569DQM74SC) Sodium Acetate368 mg  in 100 mL
POTASSIUM CHLORIDE (UNII: 660YQ98I10) (POTASSIUM CATION - UNII:295O53K152, CHLORIDE ION - UNII:Q32ZN48698) POTASSIUM CHLORIDE37 mg  in 100 mL
MAGNESIUM CHLORIDE (UNII: 02F3473H9O) (MAGNESIUM CATION - UNII:T6V3LHY838) MAGNESIUM CHLORIDE30 mg  in 100 mL
Inactive Ingredients
Ingredient NameStrength
WATER (UNII: 059QF0KO0R)  
HYDROCHLORIC ACID (UNII: QTT17582CB)  
SODIUM HYDROXIDE (UNII: 55X04QC32I)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:13985-943-0112 in 1 CARTON
11000 mL in 1 BAG
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other08/13/2018
Labeler - MWI (019926120)
Registrant - Sypharma Pty Ltd (753786292)
Establishment
NameAddressID/FEIBusiness Operations
Sypharma Pty Ltd753786292manufacture, pack, sterilize
Establishment
NameAddressID/FEIBusiness Operations
New Zealand Salt Company Limited594169799api manufacture

Revised: 8/2018
Document Id: 7e2291a3-1b6e-42c5-b474-d6360fd50092
Set id: 63bfbf33-ce89-44ba-9a87-1c6595320781
Version: 2
Effective Time: 20180827
 
MWI